Related Experiment Videos
BCL-2 expression in human colorectal adenomas and carcinomas
1Department of Pathology and Microbiology, University of Bristol, School of Medical Sciences, UK.
Oncogene
|November 1, 1994
Summary
BCL-2 oncoprotein promotes survival in colorectal tumors and metastases. Its expression may be an early event in carcinogenesis, contributing to chemotherapy resistance.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- The BCL-2 oncoprotein is recognized as a significant survival factor across various tissue types.
- Understanding BCL-2's role in colorectal cancer is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the expression of BCL-2 protein in colorectal tumor specimens and cell lines.
- To determine the potential role of BCL-2 in colorectal carcinogenesis and treatment resistance.
Main Methods:
- Immunohistochemical analysis of BCL-2 protein expression in colorectal adenocarcinomas, adenomas, and lymph node metastases.
- Assessment of BCL-2 expression in established colorectal carcinoma and adenoma cell lines.
Main Results:
- BCL-2 protein was frequently expressed in both benign (adenomas) and malignant (adenocarcinomas) colorectal tumors.
- High prevalence of BCL-2 expression was observed in colorectal cancer cell lines.
- Expression of BCL-2 was consistently detected in lymph node metastases, including in the SW620 cell line.
Conclusions:
- BCL-2 plays a role in promoting cell survival in both benign and malignant colorectal lesions.
- BCL-2 deregulation appears to be an early event in the development of colorectal cancer.
- Sustained BCL-2 expression in colorectal tumors and metastases may contribute to resistance against chemotherapy.